The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

ultragenyx.com

Stage

IPO | IPO

Total Raised

$135M

Date of IPO

1/31/2014

Market Cap

3.21B

Stock Price

45.92

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical is a developmental stage biotechnology company committed to bringing life-enhancing therapeutics for patients with rare and ultra-rare genetic diseases, also known as orphan diseases, to market. The company focuses on metabolic and rare diseases that may affect small numbers of patients, but for which the medical need is high and there are no effective treatments. Ultragenyx intends to build a sustainable pipeline of safe and effective therapies to address these clinically underserved diseases.

Ultragenyx Pharmaceutical Headquarter Location

60 Leveroni Court

Novato, California, 94949,

United States

415-483-8800

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Ultragenyx Pharmaceutical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ultragenyx Pharmaceutical is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

260 items

Ultragenyx Pharmaceutical Patents

Ultragenyx Pharmaceutical has filed 40 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Rare diseases
  • Biotechnology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/3/2018

5/17/2022

Rare diseases, Prodrugs, Membrane biology, Syndromes, Autosomal recessive disorders

Grant

Application Date

12/3/2018

Grant Date

5/17/2022

Title

Related Topics

Rare diseases, Prodrugs, Membrane biology, Syndromes, Autosomal recessive disorders

Status

Grant

Latest Ultragenyx Pharmaceutical News

Ultragenyx in-licenses rights to ABO-102 for Sanfilippo syndrome

May 18, 2022

US ultra-rare disease specialist Ultragenyx Pharmaceutical (Nasdaq: RARE) and gene and cell therapy company Abeona Therapeutics (Nasdaq: ABEO) have announced an exclusive license agreement for AAV gene therapy ABO-102 (now UX111) for the treatment of Sanfilippo syndrome type A (MPS IIIA). Under the terms of the agreement, Ultragenyx will assume responsibility for the ABO-102 program. Also, following regulatory approval, Abeona is eligible to receive… This article is accessible to registered users, to continue reading please register for free . A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please  login . If your trial has come to an end, you can  subscribe here. • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. • Daily roundup of key events in pharma and biotech. • Monthly in-depth briefings on Boardroom appointments and M&A news. • Choose from a cost-effective annual package or a flexible monthly subscription. If you are already a registered user please login . The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed Chairman, Sanofi Aventis UK

Ultragenyx Pharmaceutical Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Ultragenyx Pharmaceutical Rank

  • Where is Ultragenyx Pharmaceutical's headquarters?

    Ultragenyx Pharmaceutical's headquarters is located at 60 Leveroni Court, Novato.

  • What is Ultragenyx Pharmaceutical's latest funding round?

    Ultragenyx Pharmaceutical's latest funding round is IPO.

  • How much did Ultragenyx Pharmaceutical raise?

    Ultragenyx Pharmaceutical raised a total of $135M.

  • Who are the investors of Ultragenyx Pharmaceutical?

    Investors of Ultragenyx Pharmaceutical include HealthCap Venture Capital, TPG Biotech, F-Prime Capital, Pappas Ventures, Adage Capital Management and 7 more.

  • Who are Ultragenyx Pharmaceutical's competitors?

    Competitors of Ultragenyx Pharmaceutical include Alexza Pharmaceuticals and 4 more.

You May Also Like

P
PhytoCeutica

PhytoCeutica seeks to discover and develop botanical drugs for serious, untreated medical conditions. It does this through the utilization of a assay and informatics platform, as well as through controlled clinical trials.

CathWorks Logo
CathWorks

CathWorks is developing an image-based functional flow reserve (FFR) measurement during coronary catheterization, replacing the pressure-wire based, drug-induced measurement currently performed. CathWorks's angiogram-based FFR (FFRangio) has met the need for a less invasive FFR assessment tool, to improve real-time functional assessment leading to treatment decisions, and to make coronary catheterization procedures safer, shorter, more accurate and comprehensive.

C
Can-Fite Biopharma

Can-Fite is an Israeli science-based biopharmaceutical company with the mission to develop treatments for autoimmune diseases and cancer. The company's drugs which piggyback on a natural mechanism, are small molecules, orally administered, induce specific activity towards their target pathological cells and demonstrated an excellent safety profile in human clinical studies.

G
Genz Bio

Genz Bio is a biotechnology company developing novel IVD diagnostic solutions.

S
Symphony Allegro

Symphony Allegor is a drug company focused on treatment of acute agitation in patients with schizophrenia and bipolar disorder

Hemorai Logo
Hemorai

Hemorai develops a portable and affordable device, that is capable of providing accurate blood loss levels and alerting physicians of the actual hemoglobin and hematocrit levels, and applying correct treatment to prevent hemorrhagic shock and unnecessary blood transfusions.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.